Biomarkers for heart attack diagnosis
Pro Research Analysisby 
Searched over 200M research papers
Key Biomarkers for Heart Attack Diagnosis
Cardiac Troponins: The Gold Standard for Myocardial Infarction
Cardiac troponins (cTnI and cTnT) are the most specific and sensitive biomarkers for diagnosing heart attacks (myocardial infarction). They are released into the blood when heart muscle is damaged, making them the primary test for confirming a heart attack in clinical practice. High-sensitivity assays for cardiac troponin allow for early detection, even within hours of symptom onset, and are widely used in hospitals worldwide for both diagnosis and risk prediction of acute coronary syndromes 1234+1 MORE.
Enzyme Markers: CK-MB, AST, LDH, and Others
Enzyme markers such as creatine kinase-MB (CK-MB), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and others have historically been used to detect myocardial injury. While less specific than troponins, they can still provide supportive evidence of heart muscle damage, especially in settings where troponin testing is not available 110.
Natriuretic Peptides: BNP and NT-proBNP
B-type natriuretic peptide (BNP) and its inactive fragment NT-proBNP are primarily used to diagnose and manage heart failure, but they also provide valuable information about heart stress and can help in risk stratification after a heart attack. Elevated levels indicate increased cardiac wall stress and are associated with worse outcomes 1234+2 MORE.
Heart-Type Fatty Acid Binding Protein (H-FABP)
H-FABP is a protein released early after heart muscle injury and can help in the early diagnosis of heart attacks, especially when used alongside troponin testing. It is particularly useful in the first few hours after symptom onset 13410.
Inflammatory Biomarkers: CRP, IL-6, and MPO
Markers of inflammation such as high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and myeloperoxidase (MPO) are elevated in response to heart tissue injury and ongoing inflammation. These biomarkers are useful for risk stratification and predicting future cardiovascular events, though they are not specific for diagnosing a heart attack 1345+2 MORE.
Other Emerging and Novel Biomarkers
Several new biomarkers are being studied for their potential to improve heart attack diagnosis and prognosis. These include:
- Ischemia-modified albumin (IMA) and glycogen phosphorylase BB (GPBB) for early detection of ischemia and myocardial damage .
- Growth differentiation factor-15 (GDF-15), galectin-3, soluble ST2, and mid-regional pro-adrenomedullin (MR-proADM) for risk prediction and assessment of heart failure after a heart attack 1346+1 MORE.
- Lipoprotein-associated phospholipase A2 (Lp-PLA2) and matrix metalloproteinases (MMPs) for assessing plaque instability and risk of acute coronary events 134.
- MicroRNAs and long non-coding RNAs, which are promising for early detection and risk stratification, though their clinical use is still under investigation 13.
Conclusion
Cardiac troponins remain the gold standard for diagnosing heart attacks due to their high specificity and sensitivity. Other biomarkers, such as CK-MB, BNP/NT-proBNP, H-FABP, and inflammatory markers like CRP, provide additional diagnostic and prognostic information. Emerging biomarkers and molecular tools continue to expand the ability to detect, risk-stratify, and manage patients with suspected or confirmed heart attacks, paving the way for more personalized cardiovascular care 1234+5 MORE.
Sources and full results
Most relevant research papers on this topic